A Phase 3 interventional study of Voriconazole in Invasive Aspergillosis, sponsored by Pfizer. Terminated at 25 sites in 8 countries. Open to participants aged 2 Years to 17 Years. Per ClinicalTrials.gov, last updated 2017-06-16.
Sponsored by Pfizer · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 17 studies testing voriconazole in Aspergillosis — none open to participants now, none under way, none of them phase 3. Voriconazole · Aspergillosis.
Among the 17 studies testing voriconazole in Aspergillosis, this one is the 7th largest by enrollment, is the only one that started in 2009, is one of 5 in phase 3, and was the 9th registered.
134 studies on the registry are indexed under Aspergillosis; 10 are open to participants now.
Browse Aspergillosis studies →None of the 17 studies testing voriconazole in Aspergillosis is open now. The open studies under Aspergillosis, anywhere →
Voriconazole: first FDA approval 2002 (VFEND), first EMA approval 2002. What it is approved for, and how studies give it, is on its page →
Of the 8 Aspergillosis studies recruiting now, 6 set no upper age limit and none stop at 75 or younger; none take children under 18; 1 takes healthy volunteers.
This study: 2 Years to 17 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
17 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 5 · Phase 3 6 · Phase 4 4
First in 1997; this study’s year is marked. 1 started in 2009.
This study's enrollment of 31 is below the median of 47 across 75 interventional studies indexed under Aspergillosis.
Median enrollment 24 across the 17 interventional studies. Of the 14 that completed or were terminated, 6 (43%) have results posted.
This tab as a report to print or save as PDF → With an account.
8 of 17 have an industry lead sponsor. The 10 most frequent:
Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
11 studies in Aspergillosis by Pfizer: none open now, none under way, none of them phase 3. Of 10 finished, 7 (70%) have results posted.
Among the 11 studies in Aspergillosis by Pfizer, this one is the only one that started in 2009, is one of 3 in phase 3, and was the 6th registered.
Pfizer’s Aspergillosis studies by the year they started, since 2002.
None of the studies under way reaches primary completion within a year.
Among the 17 studies testing voriconazole in Aspergillosis, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Pfizer’s 11 in Aspergillosis:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the safety profile of voriconazole (an antifungal drug) when used in children who have invasive aspergillosis (IA) and other rare systemic fungal infections.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Children from 2 to 17 years who have possible, probable or proven invasive aspergillosis, or other rare mold infection (eg, Scedosporium and Fusarium).
Drug: Voriconazole
All subjects will receive voriconazole for a minimum of 6 weeks and a maximum of 12 weeks. All subjects must receive intravenous (IV) voriconazole for the first week of therapy. Group 1: Subjects 2 to 11 years old and subjects 12 to 14 years old with low body weight (\<50 kg) will receive 9 mg/kg IV every 12 hours (q12h) on day 1, then 8 mg/kg IV q12h starting day 2. If there is a significant clinical improvement after the first week of IV therapy, subjects may be switched to the step-down oral regimen (9 mg/kg PO q12h with a maximum dose of 350 mg PO q12h) at the discretion of the investigator. Group 2: Subjects 12 to 17 years old (excluding 12-14-year-olds weighing \<50 kg) will receive 6 mg/kg IV q12h on day 1, then 4 mg/kg IV q12h starting day 2. Similar to Group 1, subjects may be switched to the step-down oral regimen (200 mg PO q12h) at the discretion of the investigator. Oral voriconazole can be administered as tablet or oral suspension.
Number of Participants With Adverse Events (AEs)
Time frame: Baseline, daily while hospitalized, Days 7, 14, 28, 42, 84, and 114, at end of treatment, and up to 1 month post treatment
Percentage of Participants With a Global Response of Success
Percentage of participants with global response of success at Weeks 6 and at EOT (up to Week 12). Global response of success was defined as a participant who achieved a complete or partial global response per the investigator. Complete response was defined as resolution of all clinical signs and symptoms PLUS resolution of 90 percent (%) or more of the lesions visible on radiological studies and attributed to invasive aspergillosis (IA) at Baseline. Partial response was defined as clinical improvement PLUS 50% to \<90% resolution of the radiological lesions attributed to IA at Baseline.
Time frame: Weeks 6 and End of Treatment (EOT; up to Week 12)
All-Cause Mortality - Number of Participant Deaths
Number of participant deaths reported at Week 6 and at EOT (up to Week 12).
Time frame: Week 6 and EOT (up to Week 12)
Attributable Mortality - Number of Participant Deaths
Number of participant deaths attributable to study drug reported at Week 6 and at EOT (up to Week 12).
Time frame: Weeks 6 and EOT (up to Week 12)
Time to Death
Time frame: Baseline up to 1 month post treatment
| Milestone | Voriconazole: 2 to <12 Years | Voriconazole: 12 to <18 Years |
|---|---|---|
| Started | 11 | 20 |
| Completed | 8 | 17 |
| Not completed | 3 | 3 |
| Withdrew: Death | 3 | 2 |
| Withdrew: Withdrawal by subject | 0 | 1 |
| participants | Voriconazole: 2 to <12 Years | Voriconazole: 12 to <18 Years |
|---|---|---|
| With AEs | 11 | 19 |
| With serious AEs | 6 | 9 |
| With severe AEs | 5 | 8 |
| Discontinued treatment due to AEs | 1 | 0 |
| Dose reduced or temporarily discontinued due to AE | 0 | 4 |
Percentage of participants with global response of success at Weeks 6 and at EOT (up to Week 12). Global response of success was defined as a participant who achieved a complete or partial global response per the investigator. Complete response was defined as resolution of all clinical signs and symptoms PLUS resolution of 90 percent (%) or more of the lesions visible on radiological studies and attributed to invasive aspergillosis (IA) at Baseline. Partial response was defined as clinical improvement PLUS 50% to \<90% resolution of the radiological lesions attributed to IA at Baseline.
| percentage of participants | Voriconazole: 2 to <12 Years | Voriconazole: 12 to <18 Years |
|---|---|---|
| Week 6 | 40.0 (5.3 to 85.3) | 77.8 (40.0 to 97.2) |
| EOT | 40.0 (5.3 to 85.3) | 77.8 (40.0 to 97.2) |
Number of participant deaths reported at Week 6 and at EOT (up to Week 12).
| participants | Voriconazole: 2 to <12 Years | Voriconazole: 12 to <18 Years |
|---|---|---|
| Week 6 | 3 | 1 |
| EOT | 0 | 1 |
Number of participant deaths attributable to study drug reported at Week 6 and at EOT (up to Week 12).
| participants | Voriconazole: 2 to <12 Years | Voriconazole: 12 to <18 Years |
|---|---|---|
| Attributable Mortality - Number of Participant Deaths | 0 | 0 |
| days | Voriconazole: 2 to <12 Years | Voriconazole: 12 to <18 Years |
|---|---|---|
| Time to Death | 30.0 (18 to 38) | 47.5 (20 to 75) |
Non-serious events are listed at a 2% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Voriconazole: 2 to <12 Years | — | 6/11 (54.5%) | 10/11 (90.9%) |
| Voriconazole: 12 to <18 Years | — | 9/20 (45%) | 19/20 (95%) |
| Event | Voriconazole: 2 to <12 Years | Voriconazole: 12 to <18 Years |
|---|---|---|
| Septic shockInfections and infestations | 2/11 | 2/20 |
| Febrile neutropeniaBlood and lymphatic system disorders | 1/11 | 2/20 |
| Acute lymphocytic leukaemiaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/11 | 2/20 |
| NeutropeniaBlood and lymphatic system disorders | 1/11 | 0/20 |
| Cardiac arrestCardiac disorders | 1/11 | 0/20 |
| Lower gastrointestinal haemorrhageGastrointestinal disorders | 1/11 | 0/20 |
| AspergillosisInfections and infestations | 1/11 | 0/20 |
| SepsisInfections and infestations | 1/11 | 1/20 |
| HypoglycaemiaMetabolism and nutrition disorders | 1/11 | 0/20 |
| HypokalaemiaMetabolism and nutrition disorders | 1/11 | 0/20 |
| Event | Voriconazole: 2 to <12 Years | Voriconazole: 12 to <18 Years |
|---|---|---|
| PyrexiaGeneral disorders | 0/11 | 7/20 |
| DiarrhoeaGastrointestinal disorders | 3/11 | 1/20 |
| Upper respiratory tract infectionInfections and infestations | 3/11 | 1/20 |
| HypocalcaemiaMetabolism and nutrition disorders | 3/11 | 0/20 |
| HypophosphataemiaMetabolism and nutrition disorders | 3/11 | 0/20 |
| EpistaxisRespiratory, thoracic and mediastinal disorders | 2/11 | 4/20 |
| Procedural painInjury, poisoning and procedural complications | 2/11 | 2/20 |
| HypomagnesaemiaMetabolism and nutrition disorders | 2/11 | 1/20 |
| HyponatraemiaMetabolism and nutrition disorders | 2/11 | 0/20 |
| CoughRespiratory, thoracic and mediastinal disorders | 2/11 | 2/20 |
Safety population: included all participants who received at least 1 dose of study medication.
| Age, Continuous(years) | Voriconazole: 2 to <12 Years | Voriconazole: 12 to <18 Years | Total |
|---|---|---|---|
| Mean | 7.9 ± 2.3 | 14.1 ± 1.7 | 11.9 ± 3.5 |
| Sex: Female, Male(Participants) | Voriconazole: 2 to <12 Years | Voriconazole: 12 to <18 Years | Total |
|---|---|---|---|
| Female | 4 | 11 | 15 |
| Male | 7 | 9 | 16 |
Ran from May 2009 to primary completion in May 2013, 48 months.
Results were first posted in Jun 2014, 1 year 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in May 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Voriconazole